BACKGROUND: Permanent smoking cessation reduces loss of pulmonary function. Less is known in the long term about individuals who give up smoking temporarily or quitters with lower initial pulmonary function. Little is known also about the relationship between decline in pulmonary function and mortality. We examined these aspects and the association between smoking, decline in pulmonary function, and mortality. METHODS: Two middle aged male Finnish cohorts of the Seven Countries Study and their re-examinations on five occasions during a 30 year period of follow up were analysed. RESULTS: During the first 15 years (n=1007) adjusted decline in forced expiratory volume in 0.75 seconds (FEV(0.75)) was 46.4 ml/year in never smokers, 49.3 ml/year in past smokers, 55.5 ml/year in permanent quitters, 55.5 ml/year in intermittent quitters, and 66.0 ml/year in continuous smokers (p<0.001 for trend). Quitters across the entire range of baseline FEV(0.75) had a slower decline in FEV(0.75) than continuous smokers. Among both continuing smokers and never smokers, non-survivors had a significantly (p<0.001) more rapid decline in FEV(0.75) than survivors. The adjusted relative hazard for total mortality was 1.73 (95% confidence interval (CI) 1.41 to 2.11) and 1.24 (95% CI 1.02 to 1.52) in the lowest and middle tertiles of decline in FEV(0.75). Never smokers, past smokers, and quitters had significantly lower total mortality than continuous smokers, partly because of their slower decline in FEV(0.75). CONCLUSION: These results highlight the positive effect of smoking cessation, even intermittent cessation, on decline in pulmonary function. Accelerated decline in pulmonary function was found to be a risk factor for total mortality. The beneficial effect of smoking cessation on mortality may partly be mediated through a reduced decline in pulmonary function.
BACKGROUND: Permanent smoking cessation reduces loss of pulmonary function. Less is known in the long term about individuals who give up smoking temporarily or quitters with lower initial pulmonary function. Little is known also about the relationship between decline in pulmonary function and mortality. We examined these aspects and the association between smoking, decline in pulmonary function, and mortality. METHODS: Two middle aged male Finnish cohorts of the Seven Countries Study and their re-examinations on five occasions during a 30 year period of follow up were analysed. RESULTS: During the first 15 years (n=1007) adjusted decline in forced expiratory volume in 0.75 seconds (FEV(0.75)) was 46.4 ml/year in never smokers, 49.3 ml/year in past smokers, 55.5 ml/year in permanent quitters, 55.5 ml/year in intermittent quitters, and 66.0 ml/year in continuous smokers (p<0.001 for trend). Quitters across the entire range of baseline FEV(0.75) had a slower decline in FEV(0.75) than continuous smokers. Among both continuing smokers and never smokers, non-survivors had a significantly (p<0.001) more rapid decline in FEV(0.75) than survivors. The adjusted relative hazard for total mortality was 1.73 (95% confidence interval (CI) 1.41 to 2.11) and 1.24 (95% CI 1.02 to 1.52) in the lowest and middle tertiles of decline in FEV(0.75). Never smokers, past smokers, and quitters had significantly lower total mortality than continuous smokers, partly because of their slower decline in FEV(0.75). CONCLUSION: These results highlight the positive effect of smoking cessation, even intermittent cessation, on decline in pulmonary function. Accelerated decline in pulmonary function was found to be a risk factor for total mortality. The beneficial effect of smoking cessation on mortality may partly be mediated through a reduced decline in pulmonary function.
Authors: C Tabak; H A Smit; L Räsänen; F Fidanza; A Menotti; A Nissinen; E J Feskens; D Heederik; D Kromhout Journal: Thorax Date: 1999-11 Impact factor: 9.139
Authors: P D Scanlon; J E Connett; L A Waller; M D Altose; W C Bailey; A S Buist; D P Tashkin Journal: Am J Respir Crit Care Med Date: 2000-02 Impact factor: 21.405
Authors: M W Lethbridge; D M Kemeny; J C Ratoff; B J O'Connor; C M Hawrylowicz; C J Corrigan Journal: Clin Exp Immunol Date: 2010-09 Impact factor: 4.330
Authors: Penelope Baughman; Jacob L Marott; Peter Lange; Christopher J Martin; Anoop Shankar; Edward L Petsonk; Eva Hnizdo Journal: Eur J Epidemiol Date: 2012-12-14 Impact factor: 8.082
Authors: Richard Hooper; Peter Burney; William M Vollmer; Mary Ann McBurnie; Thorarinn Gislason; Wan C Tan; Anamika Jithoo; Ali Kocabas; Tobias Welte; A Sonia Buist Journal: Eur Respir J Date: 2011-12-19 Impact factor: 16.671
Authors: David M MacDonald; Anne C Melzer; Gary Collins; Anchalee Avihingsanon; Kristina Crothers; Nicholas E Ingraham; Henry Mugerwa; Matti Ristola; Jonathan Shuter; Ken M Kunisaki Journal: J Acquir Immune Defic Syndr Date: 2018-11-01 Impact factor: 3.731
Authors: David M MacDonald; Alexander D Zanotto; Gary Collins; Jason V Baker; Marcin Czarnecki; Eliana Loiza; Daniel E Nixon; Vasileios Papastamopoulos; Chris H Wendt; Robin Wood; Ken M Kunisaki Journal: AIDS Date: 2019-03-15 Impact factor: 4.177